Research Letter

Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems

JAMA Internal Medicine 10.1001/jamainternmed.2026.5774

November 16, 2026 at 11:00 AM EST

Read the full article

This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.

Corresponding Author: Joshua D. Wallach, PhD, MS, Department of Epidemiology, Rollins School of Public Health, Emory University, Claudia Nance Rollins Building, Room 3033, 1518 Clifton Rd, Atlanta, GA 30322 (joshua.wallach@emory.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.5774

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks